Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Mechanism of action of gemfibrozil on lipoprotein metabolism.
K Saku, … , B A Hynd, M L Kashyap
K Saku, … , B A Hynd, M L Kashyap
Published May 1, 1985
Citation Information: J Clin Invest. 1985;75(5):1702-1712. https://doi.org/10.1172/JCI111879.
View: Text | PDF
Research Article Article has an altmetric score of 4

Mechanism of action of gemfibrozil on lipoprotein metabolism.

  • Text
  • PDF
Abstract

Gemfibrozil is a potent lipid regulating drug whose major effects are to increase plasma high density lipoproteins (HDL) and to decrease plasma triglycerides (TG) in a wide variety of primary and secondary dyslipoproteinemias. Its mechanism of action is not clear. Six patients with primary familial endogenous hypertriglyceridemia with fasting chylomicronemia (type V lipoprotein phenotype) with concurrent subnormal HDL cholesterol levels (HDL deficiency) were treated initially by diet and once stabilized, were given gemfibrozil (1,200 mg/d). Each patient was admitted to the Clinical Research Center with metabolic kitchen facilities, for investigation of HDL and TG metabolism immediately before and after 8 wk of gemfibrozil treatment. Gemfibrozil significantly increased plasma HDL cholesterol, apolipoprotein (apo) AI, and apo AII by 36%, 29%, and 38% from base line, respectively. Plasma TG decreased by 54%. Kinetics of apo AI and apo AII metabolism were assessed by analysis of the specific radioactivity decay curves after injection of autologous HDL labeled with 125I. Gemfibrozil increased synthetic rates of apo AI and apo AII by 27% and 34%, respectively, without changing the fractional catabolic rates. Stimulation of apo AI and apo AII synthesis by gemfibrozil was associated with the appearance in plasma of smaller (and heavier) HDL particles as assessed by gradient gel electrophoresis and HDL composition. Postheparin extra-hepatic lipoprotein lipase activity increased significantly by 25% after gemfibrozil, and was associated with the appearance in plasma of smaller very low density lipoprotein particles whose apo CIII:CII ratio was decreased. These data suggest that gemfibrozil increases plasma HDL levels by stimulating their synthesis. Increased transport (turnover) of HDL induced by gemfibrozil may be significant in increasing tissue cholesterol removal in these patients.

Authors

K Saku, P S Gartside, B A Hynd, M L Kashyap

×

Total citations by year

Year: 2022 2021 2019 2018 2017 2014 2013 2011 2010 2009 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 Total
Citations: 1 2 3 2 3 1 2 1 5 4 2 2 1 4 5 1 4 6 5 10 5 9 7 7 8 3 7 9 5 8 8 1 141
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (141)

Title and authors Publication Year
Structural Analysis of Human Serum Albumin in Complex with the Fibrate Drug Gemfibrozil.
Liberi S, Linciano S, Moro G, De Toni L, Cendron L, Angelini A
International journal of molecular sciences 2022
Enhanced antihyperlipidemic potential of gemfibrozil under co-administration with piperine
S Mohanalakshmi, S Bhatt, CK Kumar
2021
Enhanced antihyperlipidemic potential of gemfibrozil under co-administration with piperine.
Mohanalakshmi S, Bhatt S, Ashok Kumar CK
2021
Pigments from Filamentous Ascomycetes for Combination Therapy
R Hromádka, Z Kejík, M Jakubek, R Kaplánek, V Šandriková, M Urban, P Martásek, V Král
Current medicinal chemistry 2019
Solubility measurement, Hansen solubility parameters and solution thermodynamics of gemfibrozil in different pharmaceutically used solvents
MA Kalam, S Alshehri, A Alshamsan, M Alkholief, R Ali, F Shakeel
Drug Development and Industrial Pharmacy 2019
Parental gemfibrozil exposure impacts zebrafish F1 offspring, but not subsequent generations
S Fraz, AH Lee, S Pollard, K Srinivasan, A Vermani, JY Wilson
Aquatic toxicology (Amsterdam, Netherlands) 2019
The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
F Hong, P Xu, Y Zhai
International journal of molecular sciences 2018
Impact of inorganic ions and pH variations on toxicity and endocrine potential of selected environmentally relevant pharmaceuticals
M Wieczerzak, B Kudłak, G Yotova, S Tsakovski, V Simeonov, J Namieśnik
Environmental pollution (Barking, Essex : 1987) 2018
Effects of Acetaminophen (Paracetamol) and Gemfibrozil on Seed Development and Antioxidant Enzyme Activities in Different Wheat Varieties
E Türkoğlu, E Osma, M Elveren
IRAN J SCI TECHNOL A 2017
Association of Serum Triglyceride Level and Gemfibrozil Consumption With Periodontal Status
F Sayar, N Akhondi, S Fallah, AA Moalemnia, A Cheraghi
Journal of Periodontology 2017
Sex difference between target levels of cholesterol-related parameters and post-PCI long-term clinical outcomes: From the FU-Registry
Y Matsuoka, A Ike, M Ogawa, K Gondo, K Shirai, M Sugihara, D Nose, H Nishikawa, A Iwata, A Kawamura, K Mori, B Zhang, S Yasunaga, S Miura, K Saku
Journal of Cardiology 2017
Intestinal nuclear receptors in HDL cholesterol metabolism
C Degirolamo, C Sabbà, A Moschetta
Journal of lipid research 2014
Therapeutic Approaches to the Regulation of Metabolism of High-Density Lipoprotein
B Zhang, E Kawachi, S Miura, Y Uehara, A Matsunaga, M Kuroki, K Saku
Circulation journal : official journal of the Japanese Circulation Society 2013
Advances in Dyslipidemia
D Soffer, M Schoen
Advances in Dyslipidemia 2013
Annual Reports in Medicinal Chemistry
JJ Liu, TW Lee
Annual Reports in Medicinal Chemistry Volume 46 2011
High-Density Lipoprotein and Coronary Heart Disease
P Natarajan, KK Ray, CP Cannon
Journal of the American College of Cardiology 2010
The effect of PPAR-α agonism on apolipoprotein metabolism in humans
A Shah, DJ Rader, JS Millar
Atherosclerosis 2010
Raising HDL cholesterol in women
DJ Eapen, GL Kalra, L Rifai, CA Eapen, N Merchant, BV Khan
International journal of women's health 2010
Should We Take High-Density Lipoprotein Cholesterol Levels at Face Value?
JO Leite, ML Fernandez
American Journal Cardiovascular Drugs 2010
High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease
EJ Schaefer
2010
Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome
JS Millar, D Duffy, R Gadi, LA Bloedon, RL Dunbar, ML Wolfe, R Movva, A Shah, IV Fuki, M McCoy, CJ Harris, MD Wang, DC Howey, DJ Rader
Arteriosclerosis, thrombosis, and vascular biology 2009
Gemfibrozil, stretching arms beyond lipid lowering
A Roy, K Pahan
Immunopharmacology and Immunotoxicology 2009
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels
DJ Hausenloy, DM Yellon
Current Opinion in Cardiology 2009
Fibrates: where are we now?
RS Loomba, R Arora
Therapeutic advances in cardiovascular disease 2009
Cytochrome P450 — physiological key factor against cholesterol accumulation and the atherosclerotic vascular process
PV Luoma
Annals of Medicine 2007
Toxicological effects of the lipid regulator gemfibrozil in four aquatic systems
JL Zurita, G Repetto, Á Jos, M Salguero, M López-Artíguez, AM Cameán
Aquatic Toxicology 2007
High-Density Lipoprotein Cholesterol-Raising Strategies
JT Kuvin, AA Alsheikh-Ali, RH Karas
Journal of Cardiovascular Pharmacology 2006
Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans?: Fig. 1
S Rashid, BW Patterson, GF Lewis
Journal of lipid research 2006
Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins
B Zhang, H Tomura, A Kuwabara, T Kimura, S Miura, K Noda, F Okajima, K Saku
Atherosclerosis 2005
High-Density Lipoprotein Cholesterol and Coronary Heart Disease:
CE Young, RH Karas, JT Kuvin
Cardiology in Review 2004
Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies
DC Chan, PH Barrett, GF Watts
The Clinical biochemist. Reviews / Australian Association of Clinical Biochemists 2004
Dyslipidemia in the metabolic syndrome
DC Chan, GF Watts
Journal of Drug Evaluation 2004
Role of Fibric Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease:
JP Desprs, I Lemieux, SJ Robins
Drugs 2004
Optimal Therapy of Low Levels of High Density Lipoprotein-Cholesterol:
ML Kashyap, S Tavintharan, VS Kamanna
American Journal Cardiovascular Drugs 2003
Evaluation of apolipoprotein A-I kinetics in rabbits in vivo using in situ and exogenous radioiodination methods
B Zhang, E Shimoji, H Tanaka, K Saku
Lipids 2003
Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy
L Calza, R Manfredi, B Farneti, F Chiodo
International Journal of Antimicrobial Agents 2003
PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance
JE Klaunig, MA Babich, KP Baetcke, JC Cook, JC Corton, RM David, JG DeLuca, DY Lai, RH McKee, JM Peters, RA Roberts, PA Fenner-Crisp
Critical Reviews in Toxicology 2003
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
S Bilz, S Wagner, M Schmitz, A Bedynek, U Keller, T Demant
Journal of lipid research 2003
Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells
D Zhu, SH Ganji, VS Kamanna, ML Kashyap
Atherosclerosis 2002
Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients
MF Chen, TD Wang, HT Yeh, HC Hsu, YT Lee
European Journal of Clinical Investigation 2001
High-density lipoprotein: Epidemiology, metabolism, and antiatherogenic effects
PP Toth
Disease-a-Month 2001
Lp A-I and Niacin: New Views of an Antiatherogenic Duo
L Saucan, EA Brinton
Arteriosclerosis, thrombosis, and vascular biology 2001
Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol
T Sakai, VS Kamanna, ML Kashyap
Arteriosclerosis, thrombosis, and vascular biology 2001
Albumin inhibits apolipoprotein AI and AII production in human hepatoblastoma cell line (Hep G2): additive effects of oleate–albumin complex
T Sakai, FY Jin, VS Kamanna, ML Kashyap
Atherosclerosis 2000
HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia
K Winkler, JR Schaefer, B Klima, C Nuber, I Friedrich, W Köster, H Gierens, H Scharnagl, M Soufi, H Wieland, W März
Atherosclerosis 2000
Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
KH Mayer, MP Dube, D Sprecher, WK Henry, JA Aberg, FJ Torriani, HN Hodis, J Schouten, J Levin, G Myers, R Zackin, T Nevin, JS Currier
Clinical Infectious Diseases 2000
Age-associated decrease in plasma cholesterol and changes in cholesterol metabolism in homozygous watanabe heritable hyperlipidemic rabbits
M Shiomi, T Ito, T Fujioka, Y Tsujita
Metabolism 2000
Preventing, stopping, or reversing coronary artery disease— triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: The need for recognition and treatment
EE Ferguson
Disease-a-Month 2000
In Vivo Metabolism of HDL, Apo A-I, and Lp A-I, and Function of HDL -A Clinical Perspective
B Zhang, K Saku, T Ohta
Journal of Atherosclerosis and Thrombosis 2000
In vivo kinetics of human apolipoprotein A-I variants in rabbits
Saku, von Eckardstein, Zhang, Liu, Jimi, Ou, Ohta, Assmann, Arakawa
European Journal of Clinical Investigation 1999
Combined Effects of Probucol and Bezafibrate on Lipoprotein Metabolism and Liver Cholesteryl Ester Transfer Protein mRNA in Cholesterol-Fed Rabbits
J Ou, K Saku, S Jimi, YL Liao, T Ohta, B Zhang, K Arakawa
Japanese Circulation Journal 1999
Effect of gemfibrozil on triacylglycerol synthesis and secretion by liver and lipoprotein lipase activity in adipose tissue of rats
K Nagao, M Sakono, M Nakayama, T Hirakawa, K Imaizumi
Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology 1999
The regulation of Acetyl-CoA carboxylase—a potential target for the action of hypolipidemic agents
MR Munday, CJ Hemingway
Advances in Enzyme Regulation 1999
Developmental and Pharmacological Regulation of Apolipoprotein C-II Gene Expression: Comparison With Apo C-I and Apo C-III Gene Regulation
Y Andersson, Z Majd, AM Lefebvre, G Martin, AV Sechkin, V Kosykh, JC Fruchart, J Najib, B Staels
Arteriosclerosis, thrombosis, and vascular biology 1999
Decrease in High Density Lipoprotein Cholesterol (HDL-C) Levels Following Gemfibrozil Therapy
AG Lacko, BJ Kudchodkar, WW Loney, MB Clearfield, S Weis
Clinical Chemistry and Laboratory Medicine 1998
No Effect of Fibrates on Synthesis of Apolipoprotein(a) in Primary Cultures of Cynomolgus Monkey and Human Hepatocytes: Apolipoprotein A-I Synthesis Increased
DM Neele, A Kaptein, H Huisman, EC de Wit, HM Princen
Biochemical and Biophysical Research Communications 1998
Principles of Medical Biology
JO Jørgensen
Principles of Medical Biology 1998
Mechanistic studies of high-density lipoproteins
ML Kashyap
The American Journal of Cardiology 1998
Treatment of Diabetic Dyslipidemia
AG MD
The American Journal of Cardiology 1998
Mechanism of action of probucol on cholesteryl ester transfer protein (CETP) mRNA in a Chinese hamster ovary cell line that had been stably transfected with a human CETP gene
J Ou, K Saku, S Jimi, T Ohta, B Zhang, HJ Pownall, Y Shimada, Y Tsujita, K Arakawa
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1998
Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet
K Nagao, S Yoshida, H Nakagiri, M Sakono, M Sato, K Imaizumi
Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology 1998
The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates
N Vu-Dac, S Chopin-Delannoy, P Gervois, E Bonnelye, G Martin, JC Fruchart, V Laudet, B Staels
The Journal of biological chemistry 1998
Estradiol Stimulates Apolipoprotein A-I– but Not A-II–Containing Particle Synthesis and Secretion by Stimulating mRNA Transcription Rate in Hep G2 Cells
FY Jin, VS Kamanna, ML Kashyap
Arteriosclerosis, thrombosis, and vascular biology 1998
Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates):
DB Miller, JD Spence
Clinical Pharmacokinetics 1998
Gene Activation, Apolipoprotein A-I/High Density Lipoprotein, Atherosclerosis Prevention and Longevity
PV Luoma
Pharmacology & Toxicology 1997
A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India
HO Sharma, SK Sharma
Indian Journal of Clinical Biochemistry 1997
A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery
M Syvänne, MR Taskinen, MS Nieminen, V Manninen, YA Kesäniemi, A Pasternack, JW Nawrocki, H Haber, MH Frick
Controlled Clinical Trials 1997
Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells: Implication for Reverse Cholesterol Transport
FY Jin, VS Kamanna, ML Kashyap
Arteriosclerosis, thrombosis, and vascular biology 1997
Mechanism of the slow induction of apolipoprotein A-I synthesis by retinoids in cynomolgus hepatocytes: involvement of retinoic acid and retinoid X receptors
A Kaptein, DM Neele, J Twisk, HF Hendriks, T Kooistra, HM Princen
Journal of lipid research 1997
Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia
CY Yang, ZW Gu, YH Xie, NV Valentinova, M Yang, D Yeshurun, JA Quion, AM Gotto
Atherosclerosis 1996
Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels
EJ Schaefer, S Lamon-Fava, T Cole, DL Sprecher, DD Cilla, CC Balagtas, JP Rowan, DM Black
Atherosclerosis 1996
Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats
BR Krause, BC Barnett, AD Essenburg, KA Kieft, BJ Auerbach, R Bousley, R Stanfield, RS Newton, CL Bisgaier
Atherosclerosis 1996
Cytochrome P450 and atherosclerosis
P Luoma
Clinical Pharmacology & Therapeutics 1996
HDL Heterogeneity and Atherosclerosis
A Tailleux, JC Fruchart, JG Parkes
Critical Reviews in Clinical Laboratory Sciences 1996
Protein-DNA Interactions at a Drug-responsive Element of the Human Apolipoprotein A-I Gene
X Zhang, ZQ Chen, Z Wang, W Mohan, SP Tam
The Journal of biological chemistry 1996
Gemfibrozil Stimulates Apolipoprotein A-I Synthesis and Secretion by Stabilization of mRNA Transcripts in Human Hepatoblastoma Cell Line (Hep G2)
FY Jin, VS Kamanna, MY Chuang, K Morgan, ML Kashyap
Arteriosclerosis, thrombosis, and vascular biology 1996
Drugs Affecting Lipid Metabolism
AM Gotto, R Paoletti, LC Smith, AL Catapano, AS Jackson
1996
Age-Related Changes Affecting Atherosclerotic Risk: Potential for Pharmacological Intervention
LG Spagnoli, A Mauriello, A Orlandi, G Sangiorgi, E Bonanno
Drugs & Aging 1996
The effects of probucol and clofibrate alone and in combination on hepatic cholesterol metabolism in the male rat
J Shand
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1995
Effects of Acipimox on the metabolism of free fatty acids and very low density lipoprotein triglyceride
JS Hannah, NL Bodkin, MS Paidi, N Anh-Le, BV Howard, BC Hansen
Acta Diabetologica 1995
Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients
J Kahri, T Sane, A Tol, MR Taskinen
Journal of Internal Medicine 1995
Section Review—Cardiovascular & Renal: Emerging Therapies in Atherosclerosis
BR Krause, DR Sliskovic, TM Bocan
Expert Opinion on Investigational Drugs 1995
Bezafibrate therapy in patients with isolated low high-density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis
MS Weintraub, I Grosskopf, G Charach, R Mor, A Rubinstein, Y Wollman, R Judevices, A Iaina
Metabolism 1995
Multiple Risk Factors in Cardiovascular Disease
AM Gotto, C Lenfant, AL Catapano, R Paoletti
1995
A New Case of ApoA-I Deficiency Showing Codon 8 Nonsense Mutation of the ApoA-I Gene Without Evidence of Coronary Heart Disease
K Takata, K Saku, T Ohta, M Takata, H Bai, S Jimi, R Liu, H Sato, G Kajiyama, K Arakawa
Arteriosclerosis, thrombosis, and vascular biology 1995
The effects of fibrates on lipoprotein and hemostatic coronary risk factors
G Schonfeld
Atherosclerosis 1994
Primary care of the renal transplant patient
JD Pirsch, R Friedman
Journal of General Internal Medicine 1994
Association of high density lipoprotein with whole blood-associated acetaldehyde levels
MR Halvorson, JK Noffsinger, BD Roberts, CM Peterson
Alcohol 1994
Drug control of reverse cholesterol transport
G Franceschini, JP werba, L Calabresi
Pharmacology & Therapeutics 1994
Combined Treatment with Pravastatin and Gemfibrozil in Patients with Refractory Familial Combined Hyperlipidaemia: A Clinical Study
VG Athyros, AA Papageorgiou, HJ Hagikonstantinou, GV Papadopoulos, CX Zamboulis, AG Kontopoulos
Drug Investigation 1994
7 Dyslipidaemia and obesity
JP Després
Baillière's Clinical Endocrinology and Metabolism 1994
Principles and Treatment of Lipoprotein Disorders
G Schettler, AJ Habenicht
1994
Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome
IE Sitno, JA Yakichuk, TC Ooi
Atherosclerosis 1993
Drugs controlling triglyceride metabolism
G Franceschini, R Paoletti
Medicinal Research Reviews 1993
Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity
J Kahri, H Vuorinen-Markkola, M Tilly-Kiesi, S Lahdenperä, MR Taskinen
Atherosclerosis 1993
Gemfibrozil increases apolipoprotein A-I and cholesterol concentrations in human peripheral lymph
D Reichl, NE Miller, JM Sterchi
European Journal of Clinical Investigation 1993
Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase
RB Simsolo, JM Ong, PA Kern
Metabolism 1993
In vivo conversion of recombinant human proapolipoprotein AI (rh-Met-proapo AI) to apolipoprotein AI in rabbits
K Saku, R Liu, K Ohkubo, H Bai, K Hirata, K Yamamoto, Y Morimoto, K Yamada, K Arakawa
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1993
Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus
M Syvänne, H Vuorinen-Markkola, H Hilden, MR Taskinen
Arteriosclerosis Thrombosis and Vascular Biology 1993
Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia
C Contacos, PJ Barter, DR Sullivan
Arteriosclerosis Thrombosis and Vascular Biology 1993
Ethanol stimulates apolipoprotein A-I secretion by human hepatocytes: Implications for a mechanism for atherosclerosis protection
RN Amarasuriya, AK Gupta, M Civen, YC Horng, T Maeda, ML Kashyap
Metabolism 1992
Postprandial Lipoprotein Metabolism in Obese Patients with Moderate Hypertriglyceridaemia: Effects of Gemfibrozil
HH Ditschuneit, M Flechtner-Mors, E Hagel, H Ditschuneit
J INT MED RES 1992
Mode of action of fibrates
AL Catapano
Pharmacological research : the official journal of the Italian Pharmacological Society 1992
Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia
KJ Williams, KA Petrie, RW Brocia, TL Swenson
Journal of Clinical Investigation 1991
Gemfibrozil in familial combined hyperlipidaemia: effect of added low-dose cholestyramine on plasma and biliary lipids
B Ödman, S Ericsson, M Lindmark, L Berglund, B Angelin
European Journal of Clinical Investigation 1991
Fibrates and triglyceride metabolism
P Schwandt
European Journal of Clinical Pharmacology 1991
Effects of Gemfibrozil and Other Fibric Acid Derivatives on Blood Lipids and Lipoproteins
P Zimetbaum, WH Frishman, S Kahn
The Journal of Clinical Pharmacology 1991
Lipids and Women’s Health
GP Redmond
1991
Cerebral Ischemia and Dementia
A Hartmann, W Kuschinsky, S Hoyer
1991
A Comparative Review of the Adverse Effects of Treatments for Hyperlipidaemia:
A Steiner, B Weisser, W Vetter
Drug Safety 1991
Management of the patient with a low HDL-cholesterol
RF Leighton
Clinical Cardiology 1990
Effect of gemfibrozil on the concentration and composition of serum lipoproteins A controlled study with special reference to initial triglyceride levels
M Mänttäri, P Koskinen, V Manninen, JK Huttunen, MH Frick, EA Nikkilä
Atherosclerosis 1990
Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia
P Pauciullo, G Marotta, P Rubba, C Cortese, MG Caruso, A Gnasso, A Fischetti, C Motti, M Mancini
Journal of Internal Medicine 1990
Metabolic regulation of apoproteins of high-density lipoproteins by estrogen and progesterone in the baboon (Papio sp)
RS Kushwaha, DM Foster, VN Murthy, KD Carey, MG Bernard
Metabolism 1990
Raising high density lipoprotein cholesterol
NE Miller
Biochemical Pharmacology 1990
Putative mechanisms of action of probucol on high-density lipoprotein apolipoprotein A-I and its isoproteins kinetics in rabbits
H Ying, K Saku, R Harada, N Takami, N Sasaki, Y Saito, K Arakawa
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1990
6 Hyperlipidaemia and hypertension
W Krone, D Müller-Wieland
Baillière's Clinical Endocrinology and Metabolism 1990
Effect of Gemfibrozil Administration on Biliary Lipid Secretion in Hyperlipidemic Patients
G Mazzella, F Bazzoli, N Villanova, P Simoni, D Festi, A Roda, R Aldini, E Roda
Scandinavian Journal of Gastroenterology 1990
Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, in Vivo Kinetics
CL Malmendier, P Alaupovic, HB Brewer
1990
Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women
EA Brinton, S Eisenberg, JL Breslow
Journal of Clinical Investigation 1989
Guar gum and gemfibrozil — an effective combination in the treatment of hypercholesterolaemia
J Tuomilehto, M Silvasti, V Manninen, M Uusitupa, A Aro
Atherosclerosis 1989
Low-dose colestipol plus fenofibrate: Effects on plasma liproproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia
P Weisweiler
Metabolism 1989
Basic considerations in the reversal of atherosclerosis: Significance of high-density lipoprotein in stimulating reverse cholesterol transport
ML Kashyap
The American Journal of Cardiology 1989
Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism
D Reichl, NE Miller
Arteriosclerosis (Dallas, Tex.) 1989
Effects of fibrates on serum lipids and atherosclerosis
CR Sirtori, G Franceschini
Pharmacology & Therapeutics 1988
Apolipoproteins in human biopsied nephrotic kidneys
K Saku, T Sata, S Naito, K Fukushima, S Takebayashi, K Arakawa
International Urology and Nephrology 1988
Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia
SW Rabkin, M Hayden, J Frohlich
Atherosclerosis 1988
Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease
PT Kuo, AC Wilson, JB Kostis, AB Moreyra, HT Dodge
American Heart Journal 1988
Lessons from the Helsinki Heart Study: Fibric acid therapy for dyslipidemia
SM Grundy
Postgraduate Medicine 1988
Focus on Fenofibrate
WV Brown
Hospital Practice 1988
Treatment of Lipid Disorders in Diabetes Mellitus
FL Dunn
Medical Clinics of North America 1988
Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins
NA Le, JC Gibson, HN Ginsberg
Journal of lipid research 1988
Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil
MS Weintraub, S Eisenberg, JL Breslow
Journal of Clinical Investigation 1987
Pharmacological treatment of lipid disorders in diabetes mellitus
MF Lopes-Virella, JA Colwell
Diabetes / Metabolism Reviews 1987
Fibric acids: Effects on lipids and lipoprotein metabolism
SM Grundy, GL Vega
The American Journal of Medicine 1987
Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives
HN Ginsberg
The American Journal of Medicine 1987
High-density lipoprotein turnover
PJ Nestel
American Heart Journal 1987
10 Mode of action of lipid-lowering drugs
R Fears
Baillière's Clinical Endocrinology and Metabolism 1987
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
MH Frick, O Elo, K Haapa, OP Heinonen, P Heinsalmi, P Helo, JK Huttunen, P Kaitaniemi, P Koskinen, V Manninen, H Mäenpää, M Mälkönen, M Mänttäri, S Norola, A Pasternack, J Pikkarainen, M Romo, T Sjöblom, EA Nikkilä
New England Journal of Medicine 1987
Lipid-Lowering Drugs: An Overview of Indications and Optimum Therapeutic Use
DR Illingworth
Drugs 1987
Gemfibrozil increases both apo A-I and apo E concentrations
BR Krause, RS Newton
Atherosclerosis 1986

← Previous 1 2 3 4 5 6 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
Referenced in 1 clinical guideline sources
32 readers on Mendeley
See more details